Abstract
Sialyllactoses (SLs) primarily include sialylated human milk oligosaccharides (HMOs) and bovine milk oligosaccharides (BMOs). First, the safety assessment of 3′-sialyllactose (3′-SL) and 6′-sialyllactose (6′-SL) revealed low toxicity in various animal models and human participants. SLs constitute a unique milk component, highlighting the essential nutrients and bioactive components crucial for infant development, along with numerous associated health benefits for various diseases. This review explores the safety, biosynthesis, and potential biological effects of SLs, with a specific focus on their influence across various physiological systems, including the gastrointestinal system, immune disorders, rare genetic disorders (such as GNE myopathy), cancers, neurological disorders, cardiovascular diseases, diverse cancers, and viral infections, thus indicating their therapeutic potential.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The evidence showing higher effects of the combination of SLs was demonstrated in detail in particular organs and diseases such as the intestine system and viral infection.
References
Aaron L, Franco OE, Hayward SW (2016) Review of prostate anatomy and embryology and the etiology of benign prostatic hyperplasia. Urol Clin North Am 43:279–288. https://doi.org/10.1016/j.ucl.2016.04.012
Bajic D, Wiens F, Wintergerst E, Deyaert S, Baudot A, Van den Abbeele P (2023) HMOs exert marked bifidogenic effects on children’s gut microbiota ex vivo, due to age-related bifidobacterium species composition. Nutrients 15:1701. https://doi.org/10.3390/nu15071701
Baker AN, Richards SJ, Guy CS, Congdon TR, Hasan M, Zwetsloot AJ, Gallo A, Lewandowski JR, Stansfeld PJ, Straube A, Walker M, Chessa S, Pergolizzi G, Dedola S, Field RA, Gibson MI (2020) The SARS-COV-2 spike protein binds sialic acids and enables rapid detection in a lateral flow point of care diagnostic device. ACS Cent Sci 6:2046–2052. https://doi.org/10.1021/acscentsci.0c00855
Bozorgmehr T, Boutin RCT, Woodward SE, Donald K, Chow JM, Buck RH, Finlay BB (2023) Early life exposure to human milk oligosaccharides reduces allergic response in a murine asthma model. J Immunol Res 2023:9603576. https://doi.org/10.1155/2023/9603576
Chen SX, He JH, Mi YJ, Shen HF, Schachner M, Zhao WJ (2020) A mimetic peptide of α2,6-sialyllactose promotes neuritogenesis. Neural Regen Res 15:1058–1065. https://doi.org/10.4103/1673-5374.270313
Cheng L, Kiewiet MBG, Groeneveld A, Nauta A, de Vos P (2019) Human milk oligosaccharides and its acid hydrolysate LNT2 show immunomodulatory effects via TLRs in a dose and structure-dependent way. J Funct Foods 59:174–184. https://doi.org/10.1016/j.jff.2019.05.023
Choi YH, Kim JH, Park JH, Lee N, Kim DH, Jang KS, Park IH, Kim BG (2014) Protein engineering of α2,3/2,6-sialyltransferase to improve the yield and productivity of in vitro sialyllactose synthesis. Glycobiology 24:159–169. https://doi.org/10.1093/glycob/cwt092
Chung TW, Kim EY, Kim SJ, Choi HJ, Jang SB, Kim KJ, Ha SH, Abekura F, Kwak CH, Kim CH, Ha KT (2017) Sialyllactose suppresses angiogenesis by inhibiting VEGFR-2 activation, and tumor progression. Oncotarget 8:58152–58162. https://doi.org/10.18632/oncotarget.16192
Dou Y, Luo Y, Xing Y, Liu H, Chen B, Zhu L, Ma D, Zhu J (2023) Human milk oligosaccharides variation in gestational diabetes mellitus mothers. Nutrients 15:1441. https://doi.org/10.3390/nu15061441
Duska-McEwen G, Senft AP, Ruetschilling TL, Barrett EG, Buck RH (2014) Human milk oligosaccharides enhance innate immunity to respiratory syncytial virus and influenza in vitro. Food Sci Nutr 5:1387–1398. https://doi.org/10.4236/fns.2014.514151
Eiwegger T, Stahl B, Schmitt J, Boehm G, Gerstmayr M, Pichler J, Dehlink E, Loibichler C, Urbanek R, Szépfalusi Z (2004) Human milk–derived oligosaccharides and plant-derived oligosaccharides stimulate cytokine production of cord blood T-cells in vitro. Pediatr Res 56:536–540. https://doi.org/10.1203/01.Pdr.0000139411.35619.B4
Faijes M, Castejón-Vilatersana M, Val-Cid C, Planas A (2019) Enzymatic and cell factory approaches to the production of human milk oligosaccharides. Biotechnol Adv 37:667–697. https://doi.org/10.1016/j.biotechadv.2019.03.014
Fong B, Ma K, McJarrow P (2011) Quantification of bovine milk oligosaccharides using liquid chromatography-selected reaction monitoring-mass spectrometry. J Agric Food Chem 59:9788–9795. https://doi.org/10.1021/jf202035m
Fuhrer A, Sprenger N, Kurakevich E, Borsig L, Chassard C, Hennet T (2010) Milk sialyllactose influences colitis in mice through selective intestinal bacterial colonization. J Exp Med 207:2843–2854. https://doi.org/10.1084/jem.20101098
Gilbert M, Cunningham AM, Watson DC, Martin A, Richards JC, Wakarchuk WW (1997) Characterization of a recombinant Neisseria meningitidis alpha-2,3-sialyltransferase and its acceptor specificity. Eur J Biochem 249:187–194. https://doi.org/10.1111/j.1432-1033.1997.t01-1-00187.x
Guo Y, Jers C, Meyer AS, Arnous A, Li H, Kirpekar F, Mikkelsen JD (2014) A pasteurella multocida sialyltransferase displaying dual trans-sialidase activities for production of 3’-sialyl and 6’-sialyl glycans. J Biotechnol 170:60–67. https://doi.org/10.1016/j.jbiotec.2013.11.013
Guo Y, Jers C, Meyer AS, Li H, Kirpekar F, Mikkelsen JD (2015) Modulating the regioselectivity of a Pasteurella multocida sialyltransferase for biocatalytic production of 3′- and 6′-sialyllactose. Enzyme Microb Technol 78:54–62. https://doi.org/10.1016/j.enzmictec.2015.06.012
Guo L, Chen X, Xu L, Xiao M, Lu L (2018) Enzymatic synthesis of 6’-sialyllactose, a dominant sialylated human milk oligosaccharide, by a novel exo-α-sialidase from bacteroides fragilis NCTC9343. Appl Environ Microbiol 84:e00071-e118. https://doi.org/10.1128/aem.00071-18
Gurung RB, Kim DH, Kim L, Lee AW, Wang Z, Gao Y (2018) Toxicological evaluation of 6’-sialyllactose (6’-SL) sodium salt. Regul Toxicol Pharmacol 95:182–189. https://doi.org/10.1016/j.yrtph.2018.03.010
Ha SH, Kwak CH, Park JY, Abekura F, Lee YC, Kim JS, Chung TW, Kim CH (2020) 3’-sialyllactose targets cell surface protein, SIGLEC-3, and induces megakaryocyte differentiation and apoptosis by lipid raft-dependent endocytosis. Glycoconj J 37:187–200. https://doi.org/10.1007/s10719-019-09902-1
Harris JE, Pinckard KM, Wright KR, Baer LA, Arts PJ, Abay E, Shettigar VK, Lehnig AC, Robertson B, Madaris K, Canova TJ, Sims C, Goodyear LJ, Andres A, Ziolo MT, Bode L, Stanford KI (2020) Exercise-induced 3’-sialyllactose in breast milk is a critical mediator to improve metabolic health and cardiac function in mouse offspring. Nat Metab 2:678–687. https://doi.org/10.1038/s42255-020-0223-8
Hauser J, Pisa E, Arias Vásquez A, Tomasi F, Traversa A, Chiodi V, Martin FP, Sprenger N, Lukjancenko O, Zollinger A, Metairon S, Schneider N, Steiner P, Martire A, Caputo V, Macrì S (2021) Sialylated human milk oligosaccharides program cognitive development through a non-genomic transmission mode. Mol Psychiatry 26:2854–2871. https://doi.org/10.1038/s41380-021-01054-9
Heida R, Bhide YC, Gasbarri M, Kocabiyik Ö, Stellacci F, Huckriede ALW, Hinrichs WLJ, Frijlink HW (2021) Advances in the development of entry inhibitors for sialic-acid-targeting viruses. Drug Discov Today 26:122–137. https://doi.org/10.1016/j.drudis.2020.10.009
Holscher HD, Bode L, Tappenden KA (2017) Human milk oligosaccharides influence intestinal epithelial cell maturation in vitro. J Pediatr Gastroenterol Nutr 64:296–301. https://doi.org/10.1097/mpg.0000000000001274
Huynh DTN, Heo KS (2021) Role of mitochondrial dynamics and mitophagy of vascular smooth muscle cell proliferation and migration in progression of atherosclerosis. Arch Pharm Res 44:1051–1061. https://doi.org/10.1007/s12272-021-01360-4
Isa P, Arias CF, López S (2006) Role of sialic acids in rotavirus infection. Glycoconj J 23:27–37. https://doi.org/10.1007/s10719-006-5435-y
Jeon J, Kang LJ, Lee KM, Cho C, Song EK, Kim W, Park TJ, Yang S (2018) 3’-Sialyllactose protects against osteoarthritic development by facilitating cartilage homeostasis. J Cell Mol Med 22:57–66. https://doi.org/10.1111/jcmm.13292
Jin Y, Heo KS (2023) Experimental model and novel therapeutic targets for non-alcoholic fatty liver disease development. Korean J Physiol Pharmacol 27:299–310. https://doi.org/10.4196/kjpp.2023.27.4.299
Jin BR, Kim HJ, Kim EY, Chung TW, Ha KT, An HJ (2019) 6’-Sialyllactose ameliorates in vivo and in vitro benign prostatic hyperplasia by regulating the E2F1/pRb-AR pathway. Nutrients 11:2203. https://doi.org/10.3390/nu11092203
Kaeley GS, Bakewell C, Deodhar A (2020) The importance of ultrasound in identifying and differentiating patients with early inflammatory arthritis: a narrative review. Arthritis Res Ther 22:1. https://doi.org/10.1186/s13075-019-2050-4
Kang LJ, Kwon ES, Lee KM, Cho C, Lee JI, Ryu YB, Youm TH, Jeon J, Cho MR, Jeong SY, Lee SR, Kim W, Yang S (2018) 3’-Sialyllactose as an inhibitor of p65 phosphorylation ameliorates the progression of experimental rheumatoid arthritis. Br J Pharmacol 175:4295–4309. https://doi.org/10.1111/bph.14486
Kang LJ, Oh E, Cho C, Kwon H, Lee CG, Jeon J, Lee H, Choi S, Han SJ, Nam J, Song CU, Jung H, Kim HY, Park EJ, Choi EJ, Kim J, Eyun SI, Yang S (2020) 3’-Sialyllactose prebiotics prevents skin inflammation via regulatory T cell differentiation in atopic dermatitis mouse models. Sci Rep 10:5603. https://doi.org/10.1038/s41598-020-62527-5
Kim D, Gurung RB, Seo W, Lee AW, Woo J (2018) Toxicological evaluation of 3’-sialyllactose sodium salt. Regul Toxicol Pharmacol 94:83–90. https://doi.org/10.1016/j.yrtph.2018.01.020
Kim EY, Jin BR, Chung TW, Bae SJ, Park H, Ryu D, Jin L, An HJ, Ha KT (2019) 6-sialyllactose ameliorates dihydrotestosterone-induced benign prostatic hyperplasia through suppressing VEGF-mediated angiogenesis. BMB Rep 52:560–565. https://doi.org/10.5483/BMBRep.2019.52.9.113
Kim JH, Yong SY, Kim SH, Baek A, Go TH, Kang DR (2022) Randomized, triple-blind, placebo-controlled study to evaluate the safety of 6’-Sialyllactose in healthy adults. Regul Toxicol Pharmacol 129:105110. https://doi.org/10.1016/j.yrtph.2021.105110
Kurakevich E, Hennet T, Hausmann M, Rogler G, Borsig L (2013) Milk oligosaccharide sialyl(α2,3)lactose activates intestinal CD11c+ cells through TLR4. Proc Natl Acad Sci U S A 110:17444–17449. https://doi.org/10.1073/pnas.1306322110
Laucirica DR, Triantis V, Schoemaker R, Estes MK, Ramani S (2017) Milk oligosaccharides inhibit human rotavirus infectivity in MA104 cells. J Nutr 147:1709–1714. https://doi.org/10.3945/jn.116.246090
Lee S-G, Shin D-H, Kim B-G (2002) Production of sialyloligosaccharides by trans-sialidase catalyzed reaction using fetuin as a sialic acid donor. Enzyme Microb Technol 31:742–746. https://doi.org/10.1016/S0141-0229(02)00212-0
Li X, Ning X, Rui B, Wang Y, Lei Z, Yu D, Liu F, Deng Y, Yuan J, Li W, Yan J, Li M (2023) Alterations of milk oligosaccharides in mothers with gestational diabetes mellitus impede colonization of beneficial bacteria and development of RORγt(+) Treg cell-mediated immune tolerance in neonates. Gut Microbes 15:2256749. https://doi.org/10.1080/19490976.2023.2256749
Lugano R, Ramachandran M, Dimberg A (2020) Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 77:1745–1770. https://doi.org/10.1007/s00018-019-03351-7
Malicdan MC, Noguchi S, Hayashi YK, Nonaka I, Nishino I (2009) Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model. Nat Med 15:690–695. https://doi.org/10.1038/nm.1956
Malicdan MC, Noguchi S, Tokutomi T, Goto Y, Nonaka I, Hayashi YK, Nishino I (2012) Peracetylated N-acetylmannosamine, a synthetic sugar molecule, efficiently rescues muscle phenotype and biochemical defects in mouse model of sialic acid-deficient myopathy. J Biol Chem 287:2689–2705. https://doi.org/10.1074/jbc.M111.297051
Meir M, Kannapin F, Diefenbacher M, Ghoreishi Y, Kollmann C, Flemming S, Germer CT, Waschke J, Leven P, Schneider R, Wehner S, Burkard N, Schlegel N (2021) Intestinal epithelial barrier maturation by enteric glial cells is GDNF-dependent. Int J Mol Sci. https://doi.org/10.3390/ijms22041887
Monaco MH, Gurung RB, Donovan SM (2019) Safety evaluation of 3’-siallylactose sodium salt supplementation on growth and clinical parameters in neonatal piglets. Regul Toxicol Pharmacol 101:57–64. https://doi.org/10.1016/j.yrtph.2018.11.008
Monaco MH, Kim DH, Gurung RB, Donovan SM (2020) Evaluation of 6’-sialyllactose sodium salt supplementation to formula on growth and clinical parameters in neonatal piglets. Nutrients 12:1030. https://doi.org/10.3390/nu12041030
Montgomery AP, Xiao K, Wang X, Skropeta D, Yu H (2017) Computational glycobiology: mechanistic studies of carbohydrate-active enzymes and implication for inhibitor design. Adv Protein Chem Struct Biol 109:25–76. https://doi.org/10.1016/bs.apcsb.2017.04.003
Muñoz-Provencio D, Yebra MJ (2023) Gut microbial sialidases and their role in the metabolism of human milk sialylated glycans. Int J Mol Sci 24:9994. https://doi.org/10.3390/ijms24129994
Ng JY, Azizudin AM (2020) Rheumatoid arthritis and osteoarthritis clinical practice guidelines provide few complementary and alternative medicine therapy recommendations: a systematic review. Clin Rheumatol 39:2861–2873. https://doi.org/10.1007/s10067-020-05054-y
Nguyen DV, Nguyen TLL, Jin Y, Kim L, Myung CS, Heo KS (2022a) 6’-Sialylactose abolished lipopolysaccharide-induced inflammation and hyper-permeability in endothelial cells. Arch Pharm Res 45:836–848. https://doi.org/10.1007/s12272-022-01415-0
Nguyen TLL, Jin Y, Kim L, Heo KS (2022b) Inhibitory effects of 6’-sialyllactose on angiotensin II-induced proliferation, migration, and osteogenic switching in vascular smooth muscle cells. Arch Pharm Res 45:658–670. https://doi.org/10.1007/s12272-022-01404-3
Nordvang RT, Nyffenegger C, Holck J, Jers C, Zeuner B, Sundekilde UK, Meyer AS, Mikkelsen JD (2016) It All starts with a sandwich: identification of sialidases with trans-glycosylation activity. PLoS ONE 11:e0158434. https://doi.org/10.1371/journal.pone.0158434
Owens GK, Kumar MS, Wamhoff BR (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 84:767–801. https://doi.org/10.1152/physrev.00041.2003
Parente F, Cucino C, Anderloni A, Grandinetti G, Bianchi Porro G (2003) Treatment of Helicobacter pylori infection using a novel antiadhesion compound (3’sialyllactose sodium salt). A double blind, placebo-controlled clinical study. Helicobacter 8:252–256. https://doi.org/10.1046/j.1523-5378.2003.00152.x
Paris G, Ratier L, Amaya MF, Nguyen T, Alzari PM, Frasch AC (2005) A sialidase mutant displaying trans-sialidase activity. J Mol Biol 345:923–934. https://doi.org/10.1016/j.jmb.2004.09.031
Park DB, Kim L, Hwang JH, Kim KT, Park JE, Choi JS, An HJ (2023) Temporal quantitative profiling of sialyllactoses and sialic acids after oral administration of sialyllactose to mini-pigs with osteoarthritis. RSC Adv 13:1115–1124. https://doi.org/10.1039/d2ra05912f
Perna VN, Dehlholm C, Meyer AS (2021) Enzymatic production of 3’-sialyllactose in milk. Enzyme Microb Technol 148:109829. https://doi.org/10.1016/j.enzmictec.2021.109829
Phipps KR, Baldwin NJ, Lynch B, Stannard DR, Šoltésová A, Gilby B, Mikš MH, Röhrig CH (2019) Toxicological safety assessment of the human-identical milk oligosaccharide 3’-sialyllactose sodium salt. J Appl Toxicol 39:1378–1393. https://doi.org/10.1002/jat.3824
Pisa E, Martire A, Chiodi V, Traversa A, Caputo V, Hauser J, Macrì S (2021) Exposure to 3’sialyllactose-poor milk during lactation impairs cognitive capabilities in adulthood. Nutrients 13:4191. https://doi.org/10.3390/nu13124191
Pisa E, Traversa A, Caputo V, Ottomana AM, Hauser J, Macrì S (2023) Long-term consequences of reduced availability and compensatory supplementation of sialylated HMOs on cognitive capabilities. Front Cell Neurosci 17:1091890. https://doi.org/10.3389/fncel.2023.1091890
Robinson RC (2019) Structures and metabolic properties of bovine milk oligosaccharides and their potential in the development of novel therapeutics. Front Nutr 6:50. https://doi.org/10.3389/fnut.2019.00050
Saso W, Yamasaki M, Nakakita SI, Fukushi S, Tsuchimoto K, Watanabe N, Sriwilaijaroen N, Kanie O, Muramatsu M, Takahashi Y, Matano T, Takeda M, Suzuki Y, Watashi K (2022) Significant role of host sialylated glycans in the infection and spread of severe acute respiratory syndrome coronavirus 2. PLoS Pathog 18:e1010590. https://doi.org/10.1371/journal.ppat.1010590
Schelch S, Eibinger M, Gross Belduma S, Petschacher B, Kuballa J, Nidetzky B (2021) Engineering analysis of multienzyme cascade reactions for 3’-sialyllactose synthesis. Biotechnol Bioeng 118:4290–4304. https://doi.org/10.1002/bit.27898
Schmölzer K, Ribitsch D, Czabany T, Luley-Goedl C, Kokot D, Lyskowski A, Zitzenbacher S, Schwab H, Nidetzky B (2013) Characterization of a multifunctional α2,3-sialyltransferase from Pasteurella dagmatis. Glycobiology 23:1293–1304. https://doi.org/10.1093/glycob/cwt066
Schmölzer K, Czabany T, Luley-Goedl C, Pavkov-Keller T, Ribitsch D, Schwab H, Gruber K, Weber H, Nidetzky B (2015) Complete switch from α-2,3- to α-2,6-regioselectivity in Pasteurella dagmatis β-D-galactoside sialyltransferase by active-site redesign. Chem Commun (camb) 51:3083–3086. https://doi.org/10.1039/c4cc09772f
Soyyılmaz B, Mikš MH, Röhrig CH, Matwiejuk M, Meszaros-Matwiejuk A, Vigsnæs LK (2021) The mean of milk: a review of human milk oligosaccharide concentrations throughout lactation. Nutrients 13:2737. https://doi.org/10.3390/nu13082737
Stencel-Baerenwald JE, Reiss K, Reiter DM, Stehle T, Dermody TS (2014) The sweet spot: defining virus-sialic acid interactions. Nat Rev Microbiol 12:739–749. https://doi.org/10.1038/nrmicro3346
Sun XL (2021) The role of cell surface sialic acids for SARS-CoV-2 infection. Glycobiology 31:1245–1253. https://doi.org/10.1093/glycob/cwab032
Tao N, DePeters EJ, German JB, Grimm R, Lebrilla CB (2009) Variations in bovine milk oligosaccharides during early and middle lactation stages analyzed by high-performance liquid chromatography-chip/mass spectrometry. J Dairy Sci 92:2991–3001. https://doi.org/10.3168/jds.2008-1642
Tarrant I, Finlay BB (2023) Human milk oligosaccharides: potential therapeutic aids for allergic diseases. Trends Immunol 44:644–661. https://doi.org/10.1016/j.it.2023.06.003
Thon V, Lau K, Yu H, Tran BK, Chen X (2011) PmST2: a novel Pasteurella multocida glycolipid α2-3-sialyltransferase. Glycobiology 21:1206–1216. https://doi.org/10.1093/glycob/cwr054
Thon V, Li Y, Yu H, Lau K, Chen X (2012) PmST3 from Pasteurella multocida encoded by Pm1174 gene is a monofunctional α2-3-sialyltransferase. Appl Microbiol Biotechnol 94:977–985. https://doi.org/10.1007/s00253-011-3676-6
Thurl S, Munzert M, Boehm G, Matthews C, Stahl B (2017) Systematic review of the concentrations of oligosaccharides in human milk. Nutr Rev 75:920–933. https://doi.org/10.1093/nutrit/nux044
Tuplin EWN, Fernandes T, Lowry DE, Cho NA, Sales KM, Patterson RA, Reimer RA (2023) Select human milk oligosaccharide supplementation in post-weanling rats affects metabolism and gut microbiota into adulthood. Obesity (silver Spring) 31:1362–1375. https://doi.org/10.1002/oby.23731
Urashima T, Asakuma S, Leo F, Fukuda K, Messer M, Oftedal OT (2012) The predominance of type I oligosaccharides is a feature specific to human breast milk. Adv Nutr 3:473s–482s. https://doi.org/10.3945/an.111.001412
Varki A (2008) Sialic acids in human health and disease. Trends Mol Med 14:351–360. https://doi.org/10.1016/j.molmed.2008.06.002
Vijay K (2018) Toll-like receptors in immunity and inflammatory diseases: past, present, and future. Int Immunopharmacol 59:391–412. https://doi.org/10.1016/j.intimp.2018.03.002
Vinjamuri A, Davis JCC, Totten SM, Wu LD, Klein LD, Martin M, Quinn EA, Scelza B, Breakey A, Gurven M, Jasienska G, Kaplan H, Valeggia C, Hinde K, Smilowitz JT, Bernstein RM, Zivkovic AM, Barratt MJ, Gordon JI, Underwood MA, Mills DA, German JB, Lebrilla CB (2022) Human milk oligosaccharide compositions illustrate global variations in early nutrition. J Nutr 152:1239–1253. https://doi.org/10.1093/jn/nxac027
Wilbrink MH, ten Kate GA, van Leeuwen SS, Sanders P, Sallomons E, Hage JA, Dijkhuizen L, Kamerling JP (2014) Galactosyl-lactose sialylation using Trypanosoma cruzi trans-sialidase as the biocatalyst and bovine κ-casein-derived glycomacropeptide as the donor substrate. Appl Environ Microbiol 80:5984–5991. https://doi.org/10.1128/aem.01465-14
Yamamoto T, Nakashizuka M, Kodama H, Kajihara Y, Terada I (1996) Purification and characterization of a marine bacterial beta-galactoside alpha 2,6-sialyltransferase from Photobacterium damsela JT0160. J Biochem 120:104–110. https://doi.org/10.1093/oxfordjournals.jbchem.a021370
Yang C, Zhang P, Fang W, Chen Y, Zhang N, Qiao Z, Troy FA 2nd, Wang B (2019) Molecular mechanisms underlying how sialyllactose intervention promotes intestinal maturity by upregulating gdnf through a CREB-dependent pathway in neonatal piglets. Mol Neurobiol 56:7994–8007. https://doi.org/10.1007/s12035-019-1628-9
Yonekawa T, Malicdan MC, Cho A, Hayashi YK, Nonaka I, Mine T, Yamamoto T, Nishino I, Noguchi S (2014) Sialyllactose ameliorates myopathic phenotypes in symptomatic GNE myopathy model mice. Brain 137:2670–2679. https://doi.org/10.1093/brain/awu210
Yu H, Chokhawala H, Karpel R, Yu H, Wu B, Zhang J, Zhang Y, Jia Q, Chen X (2005) A multifunctional Pasteurella multocida sialyltransferase: a powerful tool for the synthesis of sialoside libraries. J Am Chem Soc 127:17618–17619. https://doi.org/10.1021/ja0561690
Zhang J, Zhu Y, Zhang W, Mu W (2022) Efficient production of a functional human milk oligosaccharide 3’-sialyllactose in genetically engineered E. coli. ACS Synth Biol 11:2837–2845. https://doi.org/10.1021/acssynbio.2c00243
Acknowledgements
This research was funded by National Research Foundation of Korea (KNRF-2022R1A2C40017761231482092640102).
Funding
National Research Foundation of Korea, 2022R1A2C40017761231482092640102, Kyung-Sun Heo.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declared no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Nguyen, T.L.L., Nguyen, D.V. & Heo, KS. Potential biological functions and future perspectives of sialylated milk oligosaccharides. Arch. Pharm. Res. 47, 325–340 (2024). https://doi.org/10.1007/s12272-024-01492-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-024-01492-3